Vaccines or boosters tailored to the variant first identified in South Africa may be needed
A multi-centered French group, led by Dr. Olivier Schwartz at the Pasteur Institute of Paris, examined how antibodies from previously infected and vaccinated individuals responded to two of the SARS-CoV-2 variants of concern, those first identified in the United Kingdom (B.1.1.7) and South Africa (B.1.351).